The Manuscript is published in JBSD with the following details:

Dey, S.K, Saini, M., Dhembala, C., Bhatt, S., Rajesh, A.S., Anand, V., Das, H.K. and Kundu, S. (2021) "Suramin, Penciclovir and Anidulafungin exhibit potential in the treatment of COVID-19 via binding to nsp12 of SARS-CoV-2". *Journal of Biomolecular Structure and Dynamics*, DOI: 10.1080/07391102.2021.2000498.

Title: Suramin, Penciclovir, and Anidulafungin exhibit potential in the treatment of COVID-19 via binding to nsp12 of SARS-CoV-2

Sanjay Kumar Dey^{1,2,3}, Manisha Saini², Chetna Dhembala², Shruti Bhatt², A. Sai Rajesh⁴, Varnita Anand², Hirendra Kumar Das⁵, and Suman Kundu^{2*}

¹Center for Advanced Biotechnology and Medicine, Rutgers University, New Jersey-08854, USA

²Department of Biochemistry, University of Delhi South Campus, New Delhi-110021, India

³Dr. B.R. Ambedkar Center for Biomedical Research, University of Delhi, Delhi-110007, India

⁴Department of Biosciences and Biotechnology, Fakir Mohan University, Odisha-756020, India

⁵School of Biotechnology, Jawaharlal Nehru University, New Delhi-110067, India

Email id: sdey@acbr.du.ac.in, manishasaini.biochem@south.du.ac.in, dhembala.chetna93@gmail.com, jetsfire4@gmail.com, asrajesh.9@gmail.com, varnitaanand@gmail.com, hirendas@hotmail.com, suman.kundu@south.du.ac.in

ORCID ID for Sanjay Kumar Dey- <https://orcid.org/0000-0001-7062-9574>

ORCID ID for Manisha Saini- <https://orcid.org/0000-0003-2242-3218>

ORCID ID for Shruti Bhatt- <https://orcid.org/0000-0002-0652-1216>

ORCID ID for Suman Kundu- <http://orcid.org/0000-0002-8960-2096>

***Correspondence to:** Suman Kundu, Professor, Department of Biochemistry, University of Delhi South Campus, New Delhi-110021, India, email: suman.kundu@south.du.ac.in

Funding support: SK Dey acknowledges financial support from Prof. Eddy Arnold, Rutgers University, USA; University of Delhi (R & D Grants); and Dr. B.R. Ambedkar Center for Biomedical Research [ACBR] (R & D Grants), University of Delhi; M Saini acknowledges the Senior Research Fellowship from a DBT funded project [Project No.: BT/PR13531/MED/30/1523/2015] and non-NET fellowship from the University of Delhi; S Bhatt acknowledges the Department of Biotechnology (DBT), Government of India for a research fellowship. C Dhembala appreciates the financial support from Lady Tata Memorial Trust in the form of a research fellowship. A S Rajesh is thankful to the Government of Odisha for the Biju Patnaik Research Fellowship. S Kundu acknowledges the financial support from DBT, Government of India through extramural projects [BT/PR8391/BRB/10/1231/2013; BT/COE/34/SP15246/2015 and BT/PR13531/MED/30/1523/2015]. S Kundu also acknowledges financial support from the University of Delhi (R & D Grant; Institution of Eminence grant

IOE/FRP/LS/2020/27); UGC, Government of India (SAP program) and DST, Government of India (PURSE Program).

Word count: 7425

Number of tables: 2

Number of figures: 8

Abstract

COVID-19, for which no confirmed therapeutic agents are available, has claimed over 48,14,000 lives globally. A feasible and quicker method to resolve this problem may be 'drug repositioning'. We investigated selected FDA and WHO-EML approved drugs based on their previously promising potential as antivirals, antibacterials or antifungals. These drugs were docked onto the nsp12 protein, which reigns the RNA-dependent RNA polymerase activity of SARS-CoV-2, a key therapeutic target for coronaviruses. Docked complexes were reevaluated using MM-GBSA analysis and the top three inhibitor-protein complexes were subjected to 100 ns long molecular dynamics simulation followed by another round of MM-GBSA analysis. The RMSF plots, binding energies and the mode of physicochemical interaction of the active site of the protein with the drugs were evaluated. Suramin, Penciclovir, and Anidulafungin were found to bind to nsp12 with similar binding energies as that of Remdesivir, which has been used as a therapy for COVID-19. In addition, recent experimental evidences indicate that these drugs exhibit antiviral efficacy against SARS-CoV-2. Such evidence, along with the significant and varied physical interactions of these drugs with the key viral enzyme outlined in this investigation, indicates that they might have a prospective therapeutic potential in the treatment of COVID-19 as monotherapy or combination therapy with Remdesivir.

Keywords: SARS-CoV-2, RdRp, Non-Structural Protein 12, FDA approved Drugs, WHO-EML, COVID-19, Suramin, Penciclovir and Anidulafungin

Graphical abstract

1. Introduction

The novel coronavirus disease 2019 (COVID-19) was declared a global pandemic on the 11th of March 2020 by WHO, barely within 3 months of the emergence of its first case (1, 2). Since that initial instance, it has kept shifting its epicenter through various continents and has now spread to 215 countries and territories. It has already infected 235,607,000 people across the globe, claimed more than 48,14,000 lives, gravely impacted the countries socio-economically and even the most advanced healthcare systems have crumbled under its weight. It is a highly contagious pneumonia caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), and the symptoms include complications in the gastrointestinal tract, respiratory problems, like cough, cold, shortness of breath, fever, and may even lead to fatality in some cases.

Family of this virus have inflicted the world with similar outbreaks, not the least of which was the Spanish Flu, which during the year 1918-1920 had infected one-fourth of the world's population and killed approximately 50 million (Centers for Disease Control and Prevention, USA). Recent examples of such epidemics caused by the closely related strains include Severe Acute Respiratory Syndrome (SARS) and Middle East Respiratory Syndrome (MERS), each one spanning to more than 20 countries and killing approximately 1600 people in their wake, with a fatality rate of 10% and 35%, respectively (3). COVID-19 has a global fatality rate of 3.6%, and if the outbreak reaches anywhere near the previous scales of pandemics, this rate would translate to millions of deaths (3).

These closely related strains are members of the coronavirus (CoV) family and belong to the class of positive-stranded RNA viruses with a huge 30 kb polycistronic genome. The viral replicase polyproteins namely pp1a and pp1ab are translated by the proximal two-thirds of the 5' end of CoV genome (ORFs 1a and 1b) (4, 5). These two polyproteins are cleaved into 16 nonstructural proteins (nsps), which are essential for viral replication and transcription, thus being regarded as a potential virulence factor and drug targets for CoV (6). ORFs near the 3' end encodes the structural proteins

namely S, M, E and N which are the spike, membrane, envelope, and nucleocapsid proteins, respectively (7, 8). Out of the 16 nsps encoded by the 5' end, nsp12 houses the RdRp (RNA-dependent RNA polymerase) activity. The central catalytic subunit of the RNA-synthesizing machinery for viral replication and transcription is the RdRp, which has seven catalytic motifs (A-G). Each motif has a particular function from selection and correct positioning to the addition of the newly incorporated NTPs (Nucleoside triphosphates) to the growing chain which is carried out with the help of a set of conserved amino acid residues. RdRp is an essential viral enzyme in the life cycle of RNA viruses and has been targeted in various viral infections, including the hepatitis C virus (HCV), the Zika virus (ZIKV), coronaviruses (CoVs) and others (9-14). It has continuously served as a predominant drug target in SARS and MERS research with minimal cytotoxic effects on host cells (15). Thus, nsp12 holds potential as an attractive target to develop therapeutic agents against SARS-CoV-2. In addition, human homologs of nsp12 are not known to exist and thus drugs that target nsp12 of COVID-19 are not expected to cause major disruption in physiological processes (15).

Of late, attempts had been made to identify small molecules that could bind to nsp12 with the potential of therapeutic intervention for COVID-19 affected patients. Investigations have revealed vitamin B12, valproic acid co-A, Remdesivir, Sofosbuvir, Tenofovir and Ribavirin to be effective inhibitors of nsp12 (16-21). While *in vitro* validation and clinical trial of these molecules, except Remdesivir, are awaited for COVID-19, it is necessary to identify additional molecules with similar objectives to populate the pipeline of potential drug candidates against COVID-19. The previous investigations utilized a homology model of the protein for small molecule screening, and with the experimental (cryo-electron microscopy) three-dimensional structures of the protein having been reported (22), the exercise of small molecule screening was necessary to be re-visited.

Novel small molecules would have to undergo validation and toxicity tests and the initial rounds of clinical trials, resulting in a long-drawn process of drug discovery. To address the current pandemic swiftly, drug repositioning is a feasible method to tackle the problem of unavailability of vaccines or therapeutic agents against novel coronavirus. FDA and WHO-essential medicine list 2019 approved drugs, along with some widely prescribed and investigational drugs, provide a safer alternative as there is no requirement to test the toxicity of these drugs. Hence, in this study, we have used molecular docking, MD simulations followed by MM-GBSA to identify and characterize binding interactions of potent drugs capable of inhibiting nsp12 of SARS-CoV-2. The exercise revealed three FDA- approved drugs with the potential to treat COVID-19.

2. Materials and methods

2.1. Sequence alignment

The fasta sequence of nsp12 protein of SARS-CoV (6NUR_SARSCoV) and the newly emerged cryo-EM (6M71) structure of nsp12 of SARS-CoV-2 (6M71_SARSCoV2) were retrieved from the Research Collaboratory for Structural Bioinformatics (RCSB) database PDB (Protein Data Bank) and aligned using MultAlin software (23). Further, graphical enhancement and secondary structure elements were added using ESPript 3.0 (24).

2.2. Preparation of the target protein for docking studies

The amino acid sequence of nsp12 of SARS-CoV-2 was retrieved from NCBI (accession number: NC045512.2) and a homology model was built initially based on the cryo-EM structure of RdRp of SARS-CoV (PDB ID 6NUR) using SWISS-MODEL (25), since the earlier investigations on drug screening were based on such a homology model. In the course of completion of our manuscript, the cryo-EM structure of nsp12 of SARS-CoV-2 was reported (22) at 2.9 Å resolution in complex with nsp7 and nsp8 proteins (PDB ID 6M71). The coordinates for nsp7 and nsp8 were removed from the PDB file and the resulting PDB file was used for all further analysis of nsp12 protein structure. The structure was further prepared as above for the subsequent docking studies.

2.3. Ligand preparation

A total of 43 diverse arrays of drugs (Table S1) exhibiting medicinal values were downloaded from PubChem databank in .sdf format and converted to .mol2 extension prior to docking using UCSF Chimera (26).

2.4. Molecular docking

To evaluate the best binding energy and pose of the ligands potentially capable of inhibiting nsp12 of SARS-CoV-2 (both the model and the cryo-EM structure), molecular docking was performed in triplicates with the help of SwissDock (27), an automated web-based tool capable of predicting the molecular interactions that may occur between a target protein and a small molecule. Ten best docked poses from each independent docking run for each compound was taken for binding energy calculation while three similar but independent docking for each compound were done using SwissDock. Before initiation of docking both the proteins and the ligands were minimized using CHARMM forcefield (25). Docking experiments were executed keeping the accurate default parameters of SwissDock with no preference of defined regions (blind docking). After the completion of docking, the protein-ligand complex was examined using the UCSF Chimera (26). Many of the docking results were also verified using the professional and licensed software Schrodinger (28). Data of ligand binding energy are presented as mean of at least three independent docking experiments $\pm$ SEM (**Tables S1 and S2**). To avoid any false-positive or false-negative results from these docking experiments, we ran MM-GBSA for all of these 43 compounds (along with positive and negative controls) taking best 10 docked poses out of the SwissDock results following methods detailed in Faizul Azam et al., 2020 (29) and Celik S et al., 2019 (30) using the freely available MM-GBSA calculation server farPPI (30, 31). Based on GAFF2 and ff14SB force field combination and the GB5 procedure using farPPI server, binding energies or rescored docking energies of the 43 compounds along with controls after MM-GBSA experiments are shown in Table S1 in kcal/mol.

2.5. Molecular dynamics simulations

MM-GBSA-based rescored protein-ligand complexes with the best pose showing lowest binding energy (against the SARS-CoV-2 cryo-EM structure (PDB 6M71)) (22), namely, nsp12-anidulafungin, nsp12-penciclovir, and nsp12-suramin were subjected to molecular dynamics simulations using the Molecular Modelling Toolkit or MMTK software (32) integrated by V. Munoz-Robles and J. D. Marechal of the Computational Biotech. Chemistry team into UCSF Chimera (26).

Cryo-EM protein structure of nsp12 (PDB ID: 6M71), was processed by the ProteinPrep wizard of Schrodinger software (28) to complete missing amino acid side chains, proper configuration of N-

and C-terminal amino acids and initial energy minimization using OPLS2005 forcefield for the protein (33-35). Each protein-ligand complex was individually subjected to molecular dynamics simulations (MD simulations) using the MMTK module of UCSF Chimera. Complexes were pre-processed using the Dock-Prep tool of UCSF Chimera to remove all hydrogens and replaced with AMBER compliant atomic nomenclatures, followed by calculation of charges to all atoms including the ligands using the AMBER ff14sb and AM1-BCC forcefields based on the ANTECHAMBER algorithm (36). After adding proper hydrogens and charge calculations, protein-ligand complexes were solvated using three-point TIP3PBOX type water molecules surrounding 10 Å in each of the three directions of the complex forming a cubic box system for simulation. A cubic box system of MD simulation was generated using a 10 Å distance from each side of the protein surface. Noncovalent interactions were measured with a cut off distance of 14 Å. The particle mesh Ewald (PME) (37) method was used to calculate electrostatic interactions while Lennard-Jones interaction method (38) was used to constrain all hydrogen bonds. The system first performed 300 steps of steepest descent with energy minimization. Then, the minimized system was used to perform simulations using an NVT ensemble. The Nosé–Hoover method (39) was used to maintain a fixed temperature while Anderson Barostat (40) was used to maintain a constant atmospheric pressure (i.e. 1 ATM) using NPT ensemble. The system was heated from 0 K to 298 K using an increment of 10 K/ps time frame. The time step of each simulation was set to 2 fs and finally, production MD was run for 100,000 ps or 100 ns. Visualizations, RMSD, RMSF, Rg, as well as energy calculation and data analysis were performed with UCSF Chimera software (26). In order to obtain diverse energy parameters including SASA energy of the drugs bound to nsp-12, g_mmpbsa package was utilized (41, 42). 150 snapshots of each complex obtained from the last 10 ns of MD trajectories has been used to compute free energy as well as energy contributions of active site residues to binding energy. The dynamic cross-correlation map for the calculation and plotting of the per residue interaction analysis between motions of backbone α -carbon atoms of the drug bound nsp12 complexes during simulation was conducted by using CHARMM27 all atom forcefield (43) and plotted with the GraphPad Prism software (<https://www.graphpad.com/scientific-software/prism/>).

2.6 MM-GBSA analysis of each of the best three drugs and Remdesivir bound to nsp12:

Molecular mechanics generalized Born surface area (or MM-GBSA) (44) are arguably highly accepted thermodynamic methods for binding free energy calculations or prediction since they are more accurate than most scoring functions of molecular docking (and less computationally demanding). Thus, to better understand the drug/ligand binding affinity and binding energies, a MM-GBSA ΔG_{Bind} analysis was done for the top three docked compounds along with Remdesivir as a positive control. In an MM-GBSA analysis, the binding energy of the receptor and ligands were calculated by the following formula:

Binding energy, a Molecular Mechanics + Implicit Solvent Energy Function represented as kcal/mol

= prime - energy of the optimized complex – prime-energy of the optimized free ligand) – prime-energy of the optimized free receptor. For each of these post-simulation MM-GBSA analysis, we had included final 10 snapshots/projections (i.e. 91st to 100th ns simulated structures) of the aforesaid protein-ligand complexes namely, nsp12-anidulafungin, nsp12-penciclovir, and nsp12-suramin; and compared the same with nsp12-remdesivir complex as well. This analysis was conducted using the Prime-MM-GBSA

module of the Schrodinger Inc. where the VSGB solvation model (45) and OPLS3 force field (46) were used for energy minimization and calculations without modifying the original input partial charges of the drugs (29). Sampling method was used to minimize the system as well as the drug-receptor interactions. Finally, the results of MM-GBSA experiment were represented as MMGBSA dG binding energies in kcal/mole (29).

2.7 Interaction maps:

Three-dimensional interaction maps were prepared using Chimera (26). Two-dimensional physicochemical interaction maps were prepared using Ligplot+ and freely available visualization tool Maestro from Schrodinger Inc. (28).

3. Results and discussion

3.1. Sequence alignment of nsp12 proteins of SARS-CoV and SARS-CoV-2 do not reveal major differences in their key amino acid residues that govern RdRp activity

Recent studies have indicated that SARS-CoV-2 shares ~78% and ~51% genome similarities with SARS and MERS, respectively (47, 48). On the alignment of amino acid sequence of nsp12 of SARS-CoV-2 (PDB ID: 6M71) (22) with its closest homologue nsp12 of SARS-CoV (PDB ID: 6NUR)(4), the RdRp domain comprising three sub-domains (the palm, thumb, finger) and the seven motifs (A-G), as shown in Fig. 1 and 3, exhibited high sequence identity within the coronavirus family. Three amino acids namely, Asp760, Asp761 and Arg553 are conserved in RdRp and are reported to be important in rNTP binding and positioning of template overhang substitutions (49). When SARS-CoV-2 RdRp amino acid sequence was compared to that of SARS-CoV, the following mutations were observed: Thr⁶¹⁴Asn (motif A) and Ser⁷⁸⁶Ala (Motif D) (Fig. 1). Motifs B, C and F were, however, 100% conserved. Based on this high sequence conservation of RdRp among different corona virus species and availability of the knowledge about the active site of this enzyme, it was investigated as a key drug target to counter COVID-19. Absence of any homologous protein or a protein with similar structure or sequence in humans is another advantage of using RdRp as a drug target.

Figure 1: Amino acid sequence alignment of nsp12 protein of SARS-CoV (6NUR_SARSCov) with the sequence used for homology model (COVID19_NSP12model) and that from the cryo-EM (6M71) structure of nsp12 of SARS-CoV-2 (6M71_SARSCov2) using ESPript 3.0. The conserved as well as the non-conserved residues are highlighted in red and white, respectively, and the RdRp motif sequences (Motif A-G) are highlighted with coloured boxes.

3.2. Selection of FDA and WHO-EML 2019 approved drugs for repurposing for COVID-19 treatment:

A total of 43 drugs of different physiognomies belonging to various classes like antivirals, antimalarials, antibacterials, anti-helminths, antifungals, anticancer, antiarrhythmic, receptor agonist, calcium channel blockers, immunosuppressant, anti-diarrheal, anti-asthma and anti-inflammation were selected from the available literature on their previously demonstrated ability to treat diseases that are closely related to COVID-19 like SARS and MERS and other viral diseases (Table S1). The drugs were either FDA or WHO-EML 2019 approved for human use or widely prescribed in different parts of the world or are investigational drugs in clinical trials based on FDA recommendation (Table S1). With the status of the drugs as suitable for human consumption, the need to test toxicity of the compounds do not arise, and the drugs can be suitably repurposed for treatment of COVID-19, provided they bind the target protein with high affinity. The selected drugs were screened *in silico* in search of a potential candidate capable of inhibiting nsp12 of SARS-CoV-2 and, hence restricting the contagion. Remdesivir, a recent investigational antiviral, which entered Phase-3 clinical trial (NCT04292730) to treat COVID-19 on the basis of its ability to inhibit SARS-CoV-2 RdRp (19), was used as a positive control in the docking study as was also done very recently by Simonis A et al. (50) and Kaddoura M et al. (51), citing our preliminary publication in PrePrints (52). Tetrandrine was chosen as a negative control because while it is known to reduce the expression of Human coronavirus OC43 (HCoV-OC43) spike and nucleoside capsid protein, it is not related with RdRp as of yet.

3.3. Molecular docking and MM-GBSA analyses identified three drugs with the potential to bind to nsp12 with binding energy similar to Remdesivir-TP:

Docking, an established strategy for structure-based drug discovery, was utilized to screen the 43 drugs (Tables S1 & S2) for their ability to dock or bind to nsp12 SARS-CoV-2. A drug that binds to

the active site of the target protein or interacts with it allosterically by binding at a site away from the active site will be capable of arresting the RdRp activity and thus CoV-2 spread. Binding energy (in kcal/mol) was used as an indicator of binary complex formation, with high negative values indicating high affinity binding (Fig. 2 and Fig. S3). The positive control Remdesivir inhibits the RdRp by mimicking as a nucleoside analogue. De-phosphorylated form of Remdesivir is an inactive prodrug. Remdesivir tri-phosphate (Remdesivir-TP), the active form of the drug, is incorporated into nascent RNA strand as Remdesivir monophosphate (Rem-MP) while its cleaved pyrophosphate remains close to it and both of them together inhibits the replication (53). Remdesivir-TP is expected to yield a high binding energy, while the negative control Tetradrine, which is not known to bind to nsp12, is expected to yield low binding energy in the docking experiments. Remdesivir-TP indeed exhibited a high binding energy of of -15.97 ± 0.3 kcal/mol with the homology model as the target protein and -14.22 ± 0.33 kcal/mol with the cryo-EM structure as the target protein. Tetradrine, on the contrary, exhibited binding energies of -5.59 ± 0.008 and -7.36 ± 0.006 kcal/mol against the homology model and experimental structure, respectively (Fig. 2, Fig. S3, and Tables S1, S2). Thus, drugs with binding energy equivalent to that of Remdesivir-TP were considered as potential drugs, with -10 kcal/mol as the stringent cut off binding energy for consideration as a candidate drug for COVID-19.

Figure 2: Bar graph representing the binding energies (kcal/mol) of the selected FDA-approved, WHO-EML 2019, investigational and widely prescribed drugs when docked to nsp12 of SARS-CoV-2 cryo-EM structure (PDB ID: 6M71) estimated by SwissDock. Remdesivir-TP and Tetradrine, FDA investigational antivirals, were

used as positive and negative controls, respectively, for the docking experiments *in silico*. Error bars are SEM for each compound as shown in Tables S1 and S2.

Molecular docking of all the 43 drugs to nsp12 SARS-Cov-2 generated the best-fit pose of the ligand and protein and the resulting binding energies are shown in Fig. 2, Fig. S3 (and Table 1). Penciclovir (Penciclovir-TP is the active form), an antiviral, Anidulafungin, an antifungal, and Suramin, an antimicrobial, showed binding energies of (mean of $n=3$) -11.35, -11.66 and -12.86 kcal/mol, respectively (Table 1; Fig. 2), as compared to the positive control (-14.22 kcal/mol) considering the cryo-EM structure as the model. The three drugs above are thus expected to inhibit nsp12 of SARS-Cov-2 in a manner similar to Remdesivir-TP. The binding energies of the drugs with the homology model and cryo-EM structures showed differences in their values but the trend overall was similar in both the cases.

In addition to the three drugs indicated above with binding energies equivalent to Remdesivir-TP, the drugs Eltrombopag, Ombitasvir, Digitoxin and Ribavirin also displayed binding energies close to -10 kcal/mol, which may be considered to be significant as well (Fig. 2; Table 1). These drugs thus may also be considered for treatment of COVID-19 along with Penciclovir, Anidulafungin and Sumarin. The fact that Eltrombopag has recently been reported (54) as a potent inhibitor of nsp12 validates our study. Additionally, these 43 compounds along with the positive and negative controls were subjected to MM-GBSA analysis or calculation of re-scoring of docking energies and the results are summarized in the Table S1 in kcal/mol with the help of farPPI server.

3.4. The lead drugs interact with nsp12 in the RdRp domain involving multiple motifs, with motifs A and F being common to all the three drugs:

Molecular docking provided the best-fit pose of the ligand in the protein structure and this allowed analysis of the interactions of the drugs with the motifs and the amino acid side chains lining the motifs. Such analysis assures that the drugs will inhibit RdRp activity, if they bind in this domain consisting of seven motifs (Fig. S1). The three best drugs indeed bound to the RdRp domain using more than one motif in each case (Fig. 3). The side chains that interact with the drug molecules were also identified (Fig. 4) indicating the ability of these molecules to fit inside the protein complex comprising of nsp7, 8 and 12. Such interaction analysis would also provide scope for lead optimization in the future, if it is necessary to augment the binding of the drugs to nsp12; however, the optimized molecules would need to be subjected to toxicity tests and clinical trials yet again.

Figure 3: Top three leads docked to the RdRp region of nsp12 (SARS-CoV-2, PDB ID: 6M71). A) Penciclovir, B) Anidulafungin, and C) Suramin.

Figure 4: Interaction maps of A) Penciclovir, B) Anidulafungin and C) Suramin with SARS-CoV-2 nsp-12. Green lines depict hydrogen bonds and eye shaped residues exhibits hydrophobic interactions.

Penciclovir-TP binds to motifs A, C and F where it forms hydrogen bonds with CYS622, SER759, ASP760, and ASP761 and van der Waals interactions with THR556, TYR689 (Figs. 3 and 4; Table 2). This was reported earlier by Zhang et al. (2020) as well, indicating the validity of our investigation (49). Anidulafungin forms hydrogen bonds with ARG555, THR556, SER759, and ASP760 and van der Waals interactions with TYR455, LYS577, TYR619, and SER682, all of which lie in motifs A, C and F (which are involved in positioning of incoming NTPs) (Figs. 2 and 3; Table 1). Suramin forms van der Waals interactions with THR556, THR591, SER592, THR687 and SER759 and hydrogen bonds with ASN496, LYS500, CYS813, SER814, TYR680, and SER682, in motifs A, B and F (enabling the positioning of the ribose moiety of NTPs with H-bond formation with 2' OH) (Figs. 3 and 4; Table 1). However, Remdesivir-TP hydrogen bonds with ASN496, ASN497, LYS500, ARG569 and GLN573 (Fig. S4), which are different from the interactions of the three drugs above. It is interesting to note that the motifs A and F are common in interactions of all the three repurposed drugs with nsp12, while B and C vary between the three. None of these drugs, however, interact with motif G (which forms polar interaction with template RNA) as with Remdesivir-TP. Motifs A and F are at the centre of the nsp12 protein and on the top segment of the RdRp domain, while motif G is more toward the surface (Figs. S1 and S1). The central non-covalent interactions of the three drugs make them unique compared to Remdesivir-TP and the potential utilization of these drugs individually or in combination with Remdesivir-TP for the successful inhibition of RdRp activity needs to be explored. We thus expect the three drugs to hinder RdRp activity, thus blocking replication and transcription and eventually viral propagation. Examination of docked poses also unveiled substantial information about the non-covalent interactions between the protein and the ligands (Figure 3; Figure 4; Table 1) and they were varied and different from Remdesivir. This necessitates that the three drugs are also considered for treatment of COVID-19 since they might result in new efficacies hitherto not observed for Remdesivir.

For all of these 43 compounds, best 10 docked poses out of the SwissDock results were taken and following methods detailed in Faizul Azam et al., 2020 (31), rescoring of binding energy was performed to avoid any false-positive/false-negative results from these docking experiments using the freely available MM-GBSA calculation server farPPI (32). MM-GBSA analysis too depicted Suramin, Anidulafungin, and Penciclovir as the top three compounds with lowest deltaG (or re-scored binding energy) values of -154.73 kcal/mol, -143.26 kcal/mol, and -152.36 kcal/mol, respectively, which are similar to the binding energy of Remdesivir (-157.59 kcal/mol) (Table S1).

3.5. MD simulation of the lead drugs bound to SARS-CoV-2 nsp12 revealed local conformational changes that might stabilize drug binding:

MM-GBSA-based re-scored top three protein-ligand complexes with the best pose showing lowest binding energy (against the SARS-CoV-2 cryo-EM structure (PDB 6M71)) (20), namely, nsp12-

anidulafungin, nsp12-penciclovir, and nsp12-suramin were subjected to molecular dynamics simulations (Fig. 5) to allow conformational changes in the complexes, if any, mimicking such changes in solutions where dynamics reigns supreme and the interactions observed are meaningful. MD simulations of Penciclovir bound to nsp12 indicated an overall minimal structural change indicating that the docked structures were similar to the highest energy minimized conformations on the ns time scale. The longer time needed to stabilize Suramin bound nsp12 structure was probably due to the complex chiral structure of the drug undergoing a number of alternative physico-chemical bond breaking and making to finally obtain its lowest energy structure. Energy parameters after the MD simulation indicated that Suramin-nsp12 interaction was the most stable ($\Delta G = -852.3$ kcal/mol) followed by the interaction of the drugs Penciclovir ($\Delta G = -851.01$ kcal/mol) and Anidulafungin ($\Delta G = -849.95$ kcal/mol) (Table S2). While Suramin displayed the highest van der Waals interactions with nsp12 after MD simulations, Anidulafungin exhibited additional electrostatic interaction, which confirmed and corroborated well with the interaction maps of each of these drugs with the various amino acid side chains of SARS-CoV-2 nsp12 (Fig. 5). These interaction maps revealed that Suramin formed two new H-bonds with THR556 and ARG553 (Fig. 5). Penciclovir formed four new H-bonds with ASP623, ARG553, ARG555 and THR556 as compared to the pre-simulation docking results. This is a new finding previously not reported by Zhang et al. (49) (Fig. 5). Anidulafungin stabilized its binding by H-bonds with ARG555, ARG556, ASP623, CYS622 and electrostatic interactions with ARG553 probably due to the presence of multiple oppositely charged atoms in the structure of the drug near its surrounding protein surface (Fig. 5). Overall, the MD simulation results confirmed the stable binding of the three drugs candidates with nsp12 and the novel physical interactions, which may be validated further *in vitro* and *in vivo* and be considered for the treatment of COVID-19.

Tables 1: Physico-chemical interactions of the repositioned drugs with SARS-CoV-2 nsp12

Drug and Its Chemical Structure	Hydrogen bonds with RdRp	Electrostatic interactions with RdRp	van der Waals interactions with RdRp	Hydrophobic interactions with RdRp
Penciclovir- triphosphate $(C_{10}H_{18}N_5O_{12}P_3)$	CYS622, SER759, ASP760, ASP761	ASP760, ASP761	THR556, TYR689	ILE589, ALA688, LEU758
Anidulafungin $(C_{58}H_{73}N_7O_{17})$	ARG555, THR556, SER759, ASP760	ASP452, ARG553, ASP623, ARG624	TYR455, LYS577, TYR619, SER682	ALA554, ALA580, GLY590, LEU758

Suramin $(C_{51}H_{40}N_6O_{23}S_6)$	ASN496, LYS500, CYS813, SER814, TYR680, SERS682	ARG553, ASP623, ASP760, ASP761, ASP865	THR556, THR591, SER592, THR687, SER759	LEU576, ALA580, ILE589, GLY590, PHE594, GLY683, ALA685, ALA688, LEU758, GLN815
---	---	--	--	--

Figure 5: The RMSD of the backbone atoms of SARS-CoV-2 nsp12 structure (PDB ID: 6M71) relative to their energy minimized complex structures as a function of time and interaction maps of the three leads with SARS-CoV-2 nsp12 after 100 ns MD simulation depicting the amino acid residues in nsp12 that physico-chemically interact with the drugs. [A] RMSD plot from initial MD trajectory of 0 ns to final trajectory at 100 ns showing almost similar but a low total change in RMSD of ~ 0.8 Å for complexes of each of the three leads (Suramin (black), Penciclovir (red) and Anidulafungin (blue)) against SARS-CoV-2 nsp12. [B-D] Interaction maps of the three leads with SARS-CoV-2 nsp12 after 100 ns simulation depicting the amino acid residues in nsp12 that interact with the drugs. Magenta lines depict hydrogen bonds. [B] Anidulafungin, [C] Suramin and [D] Penciclovir interacting with SARS-CoV-2 nsp12.

The root mean square fluctuation, RMSF, is the fluctuation of each atom around its average position. Atomic fluctuations of the C α atoms of nsp12-bound to either of Suramin, Anidulafungin, or Penciclovir, were measured in the last 10 ns and depicted in Figure 6. It is evident from the figure that overall fluctuations of nsp12 is higher in case of Suramin, than Penciclovir and Anidulafungin. It was observed that in case of nsp12-suramin complex, most dynamic amino acid residues of nsp12 were Asn496, Lys500, Arg553, Thr556, Leu576, Ala580, Ile589, Gly590, Thr591, Ser592, Phe594, Asp623, Tyr680, Ser682, Gly683, Ala685, Thr687, Ala688, Leu758, Ser759, Asp760, Asp761, Cys813, Ser814, Gln815, and Asp865 (Figure 6). Similarly, for nsp-12-penciclovir and nsp-12-anidulafungin complexes, most dynamic residues were Asp452, Tyr455, Arg553, Ala554, Arg555, Thr556, Lys577, Ala580, Ile589, Gly590, Tyr619, Cys622, Asp623, Arg624, Ser682, Ala688, Tyr689, Leu758, Ser759, Asp760, and Asp761 (Figure 6). These results imply that all three lead compounds/drugs kept continuous interactions with amino acids residues at the vicinity of their binding which are similar to docked poses and this dynamism could be evident from the proteins overall. Movement during the 100 ns MD simulation period. This is an expected scenario in case of a ligand-protein binding.

Figure 6: The per-residue RMSF plots for the energy minimized complexes of the top three drugs (Suramin, Anidulafungin, and Penciclovir) with the nsp12 after 100 ns MD simulation depicting the key amino acid residues fluctuating during the corresponding simulation.

Radius of gyration or R_g values were also calculated to find the extent to which nsp12 maintain its folded structures in presence of the three drugs. Over a period of 100 ns MD simulation, while R_g value of nsp12 diverted by about 0.2 Å in case of nsp12-penciclovir complex, the same changed to a higher extent in case of both nsp12-anidulafungin and nsp12-suramin complexes in the range of 0.25 Å and 0.3 Å, respectively. Nevertheless, this insignificant decrease in the R_g value with an increase in MD simulation time indicates insignificant changes in the side chain conformation of nsp12 protein except the sites that interact with the corresponding drugs. These results indicate that nsp12 will maintain its folded structures in the presence of the three drugs and the interactions are expected to be stable.

The dynamical per residue interaction analysis represented by a residue cross-correlation map for the correlated motions, averaged over a time period of 0.5 ns to 100 ns, is shown in Figure 7. In general, correlations/interaction between mid- to long-range separated portions of the protein, in sufficiently long converged molecular dynamics simulations, decipher the dynamic features brought about by the nature of the protein (nsp12) or its bound ligand/drug like in the present case: Suramin/Penciclovir/Anidulafungin. Usually, positive correlations comprise adjacent groups or amino acid residues, which move as a group. On the other hand, anticorrelated motions, comprise amino acids/motifs at long- and mid-range across the active sites. In Figure 7, the regions colored black to dark blue are sufficiently anticorrelated (please vide the color scale for the amount of correlation or

anticorrelations indicated in the plots). The diagrams in the Figures 7a, 7b, and 7c are diagonally symmetric. The first three regions of the per residue interaction or correlation map averaged from 0.5 to 100 ns (Figure 7a and 7b) for nsp12-penciclovir and nsp12-anidulafungin comprises of the anticorrelated motions of residues 750-765 (motif A) with residues Leu758, Ser759, Asp760, and Asp761; and 534-577 (motif F in the catalytic RdRp domain) with residues Arg553, Ala554, Arg555, Thr556, and Lys577; and 604-624 (catalytic motif A) with residues Tyr619, Cys622, Asp623 and Arg624. Similarly, nsp12-suramin complex (Figure 7c) comprises of the anticorrelated motions of residues 680-710 (motif B) with residues Tyr680, Sers682, Gly683, Ala685, Thr687, and Ala688; and 590-623 (motif A in the catalytic RdRp domain) with residues Phe594, and Asp623; and 534-556 (catalytic motif F) with residues Arg553, and Thr556. These anticorrelated amino acid residues traverse the active site and involve most of the RdRp domain of the nsp12 protein.

Figure 7: Calculated residue–residue-interaction-based correlated motions (dynamic cross-correlation map) within nsp12 from 0.5 ns to 100 ns molecular dynamic simulation of the nsp12-penciclovir/nsp-12-anidulafungin/nsp12-suramin complex. (A) nsp12-penciclovir, (B) nsp-12-anidulafungin, and (C) nsp12-suramin complex.

3.6. MM-GBSA analysis of the best three drugs bound to nsp12 complexes reveals similar binding affinities of Suramin, Anidulafungin and Penciclovir in comparison to Remdesivir:

Molecular mechanics generalized Born surface area or MM-GBSA (44) analysis of nsp12 complexes of the best three compounds namely, Suramin, Anidulafungin and Penciclovir indicated similar binding energies like that of Remdesivir (Supplementary Table S3). For each of these post-simulation MM-GBSA analysis, we had included final 10 snapshots/projections (i.e. 91st to 100th ns simulated structures) of the aforesaid protein-ligand complexes namely, nsp12-anidulafungin, nsp12-penciclovir, and nsp12-suramin; and compared the same with nsp12-remdesivir complex as well. The PRIME energies for Remdesivir, Suramin, Anidulafungin and Penciclovir were revealed to be -37504, -37129, -37055, and -36944 cal/mol which were almost similar (Table S4). However, the prime-MMGBSA dG binding energies for Suramin (-89 cal/mol) was far better than Anidulafungin (-49 cal/mol) and Penciclovir (-30 cal/mol), but similar to Remdesivir (-93 cal/mol) (Table S4). These results are more reliable than just docking scores and further increases reliability when presented in addition to MD simulations. Their sufficiently low binding energies confirm strong interactions of Suramin, Anidulafungin, and Penciclovir with nsp12, like Remdesivir.

In addition to hydrophobic, and electrostatic interaction, it was observed that the stability of Anidulafungin, Suramin, and Penciclovir in the RdRp domain of the nsp12 was also partially supported by the SASA energy with almost similar extent for all three drugs as calculated by the g_mmpbsa analysis. SASA energy for drug bound nsp12 are as follows: -8.09 ± 1.42 KJ/mol for nsp12-penciclovir complex, -7.83 ± 1.83 KJ/mol for nsp12-anidulafungin complex, -8.13 ± 2.04 KJ/mol for nsp12-suramin complex, and -8.01 ± 2.12 KJ/mol for nsp12-remdesivir complex.

Fig. 8: Detailed structural analysis of complexes formed between nsp12 and each of the top three leads and Remdesivir as a control highlighting electro-positive (blue surface) and electro-negative (red surfaces) regions of the protein favorable for interactions with oppositely charged atoms of the small drug molecules. A) Domain architecture of nsp12 with an emphasis on residue numbers, nsp12 complexes bound to B) Remdesivir, C) Suramin, D) Anidulafungin, and E) Penciclovir.

3.7. Penciclovir binds near the incoming nucleotide binding sites while Anidulafungin and Suramin binds near the palm of the RdRp revealing differential binding modes of these three drugs to nsp12:

The nsp12 protein is composed of a NiRAN (N-terminal nidovirus associated nucleotidyl transferase) domain followed by an interface and a C-terminal RdRp domain (**Fig. 8A**). RdRp is the main catalytic house of nsp12 consisting of a finger, palm and a thumb domain which have relatively conserved motifs. For example, G and F are conserved motifs of finger domain while A to D including some part of E forms a conserved motifs of palm domain (**Fig. 8**) (22). Our docking analyses showed that all three hit molecules interacted with key amino acids such as ASP760 and ASP761 which are

part catalytic centre of palm domain, thus, they may interfere with catalytic activity or metal ion-chelation. Anidulafungin made electrostatic interaction with ARG553 and ASP623. These amino acids are vital for template position in rNTP binding and sugar recognition domains (**Fig. 8**). Interestingly, the structural comparison of RdRp-Suramin and RdRp-Remdesivir complex revealed that first suramin molecule inhabits the -1 to -3 position of RNA template strand while the second Suramin occupies -4 to +1 place of primer strand. These findings indicate that two Suramin molecules can hinder interaction of RNA template-primer formation as well as effectively block the NTP entry at the palm domain (**Fig. 8**) (PDB Id: 7D4F).

3.8. FDA or WHO-approved drugs Penciclovir, Anidulafungin and Suramin are potential inhibitors of nsp12 and suitable for clinical trials for COVID-19 treatment:

Penciclovir, Anidulafungin and Suramin, identified in the present study, have immense potential for the inhibition of SARS-CoV-2 RdRp activity as evident from the above findings. The former two are FDA approved and the latter (Suramin) is listed as a drug in WHO Essential medicine list-2019. These drugs can thus be tested directly in humans inflicted with COVID-19. Various characteristics of the drugs along with their dosage regimen are summarized in Table 2 for due consideration by the scientific and medical community. Penciclovir (trade name-Denavir) (55) is a synthetic nucleoside analogue, an acyclic guanine derivative. It is an antiviral drug whose active form Penciclovir-TP is used for the treatment of various herpesvirus infections. In its active form, Penciclovir binds with a much higher affinity to viral polymerase than human polymerase, thus impairing viral replication. This accounts for the low cytotoxicity of healthy host cells (56).

Anidulafungin (trade name-Eraxis and Ecalta) is a synthetic antifungal drug, generally used for the treatment of *Candida* infections. It disrupts fungal cell wall synthesis by inhibiting the enzyme complex 1,3- β -D-glucan synthase which is involved in the synthesis of 1,3- β -D-glucan, a component of the fungal cell wall. This leads to cell death and inhibition of fungal growth (57).

Suramin (trade names -309 F, Antrypol, Bayer 205, Belganyl, Fournau 309, Germanin, Moranyl, Naganin, Naganol, Naphuride) is a synthetic sulphated naphthylamine with multiple biological effects. In the 1920s it was found as a treatment for African trypanosomiasis (African sleeping sickness), wherein it acts by inhibiting the enzymes of energy metabolism of the parasite. It can inhibit many other enzymes and proteins like RNA polymerase, reverse transcriptase, thymidine kinase, dihydrofolate reductase, urease, hexokinase and others. Hence, the precise mechanism of action remains unclear (58). Suramin has been identified with various other biological functions, for example, it is used in the treatment of cancer (59) as well as an antiviral agent against HIV (60, 61).

Table 2: Repositioned drugs as potential inhibitors of nsp12/RNA-dependent RNA polymerase (RdRp) of SARS-CoV-2 and related information

Drug	Mechanism of Action	Physical Properties	Dosing Regimen	Side effects	Current application
Penciclovir (Penciclovir-triphosphate)	Nucleoside analogue inhibits viral replication	A. Physical State: White to pale yellow solid B. Solubility: i) Penciclovir • 0.2 mg/mL in methanol, 1.3 mg/mL in	• Administration: Oral (tablet form) and cream • Regimen: Herpes liabilis • Famciclovir (Prodrug)	Negligible to normal cells Some trials suggest headache, oral/pharyngeal	Approved for Herpes Simplex virus (Herpes liabilis)

		propylene glycol, and 1.7 mg/mL in water ii) Famciclovir (Prodrug) • Soluble in acetone and methanol. • Hygroscopic below 85% relative humidity • Soluble (>25% w/v) in water (25°C)	<ul style="list-style-type: none"> Initial episode: 250 mg PO q8hr for 7-10 days Suppressive therapy: 250 mg PO q12hr for 12 months Recurrent episodes: 1500 mg PO once. Penciclovir 0.1%(10mg/g)- apply q2hr while awake for 4 days 	edema, and parosmia	
Anidulafungin	Repress fungal cell wall formation by inhibiting 1→3-β-D glucan synthase	A. Physical State: White to off-white powder B. Solubility: Eraxis formulation of Anidulafungin is soluble in 0.9% saline	Administration: Intravenous (3.33 mg/mL) Regimen: • Day 1: 200 mg IV infusion, THEN • Day 2 and thereafter: 100 mg/day IV Continued for 14 days after last positive culture	Not determined extensively. Some reported hepatic and hypersensitive adverse events	Approved for candedemia
Suramin	Mechanism unknown. Trypanocidal activity; inhibits enzymes involved with the oxidation of reduced NADH	A. Physical state: A white to off-white powder B. Solubility: Soluble in DMSO, water	Administration: Intravenous Regimen: Trypanosomiasis • 100-200 mg (test dose) IV, then 1 g IV on days 1, 3, 7, 14, 21	Nausea, vomiting and discomfort	Approved for the treatment of African trypanosomiasis and river blindness

4. Conclusion:

The nsp12 of SARS-CoV-2 seems to be a potential drug target due to its highly conserved architecture and catalytic functions. The present study identified three potential drugs having similar binding energies when compared to nsp12-Remdesivir-TP, which recently got FDA approval and is currently under extensive use for COVID-19 treatment, and which have unique interactions with the protein as compared to Remdesivir-TP. These three drugs in the current study may inhibit SARS-CoV-2 RdRp activity as evident from the findings above and are thus expected to be of use in the treatment of COVID-19 as well. Penciclovir (Denavir) (55) is a synthetic guanine nucleoside analogue (Table 2). Anidulafungin (Eraxis) is a synthetic antifungal drug that disrupts fungal cell wall synthesis, generally used for *Candida* infections (57). Suramin is a synthetic sulphated naphthylamine with multiple biological effects (58-61). While, the first two are FDA approved and the latter (Suramin) is listed as a drug in WHO Essential medicine list-2019. These drugs can thus be tested directly in humans inflicted with COVID-19. We have summarized various characteristics of the drugs along with their dosage regimen in Table 2 for due consideration for the scientific and medical community. It also opens up avenues for lead optimization, based on the detailed interactions presented here, in the search of highly potent novel entities to bind specifically to nsp12. The lead optimized drugs, if any, however, will need to be subjected to toxicity evaluation and clinical trials.

Existing experimental and clinical studies fortify our findings. Amongst the selected drugs, Suramin, the only reported non-nucleoside inhibitor of norovirus RdRp (62), was recently shown to exhibit antiviral activity against the SARS-CoV-2 cell lines (VERO E6) by targeting initial stages of replication in the viral life cycle (63). The clinical benefits of Suramin against COVID-19 infection in humans are being explored in clinical trials as well (ChiCTR2000030029). Furthermore, we

demonstrated that Penciclovir potentially binds to the catalytic center of the SARS-CoV-2 RdRp and it has been previously established that it reduces the COVID-19 infection but with a higher half-maximal effective concentration ($EC_{50}=95.96\ \mu\text{M}$) compared to that of Remdesivir ($0.77\ \mu\text{M}$). This indicates that it might require high concentrations of the nucleoside analog to reduce the viral infection; nonetheless, this drug provides an option for treating the deadly disease (64). Recent reports by Simonis A et al. (50) and Kaddoura M et al. (51) have also endorsed our claims for Penciclovir. Finally, experimental evidences have also revealed that Anidulafungin inhibits viral infection with lower half maximal inhibitory concentration ($IC_{50}=4.64\ \mu\text{M}$) compared to that of Remdesivir ($11.41\ \mu\text{M}$) against SARS-CoV-2 and is a potential candidate (65). Though claims above are promising but the results predicted and discussed in the present investigation are solely based on *in silico* methods and it would require further experimental evaluation into their molecular mode of action. Nonetheless, similar studies have been performed recently using other protein targets of SARS-CoV-2, such as nsp15 and Mpro (viral main protease) (66, 67). This justifies an optimal procedure to discover bioactive molecules to inhibit the virus. For instance, similar computational analyses have shown the inhibitory potential of acridinedione analogues (67) as well as various polyphenols and phytochemicals extracted from *Broussonetia papyrifera* and *Torreya nucifera*, respectively, against the Mpro of SARS-CoV-2 (68, 69). Studies also have been deployed by Bhardwaj et al., 2020 where they docked 65 bioactive molecules of tea plant against Mpro (68). Ghosh et al, 2020 also followed similar chronology of steps and came up with three polyphenols, which can be used as potential inhibitors against SARS-CoV-2 Mpro (69). Yet another study used *in silico* structure based method to target approved and investigational drugs to the interface of nsp12 and nsp8 (70). This further validates that though experimental analysis and clinical trials are needed for a candidate drug but *in silico* approach can help ease the long-drawn procedure of drug discovery by providing us promising leads in a less resource dependent manner.

It is to be noted that while all the existing reports targeting nsp12 utilized experimental cryo-EM structure for docking studies, ours is the first demonstrating dynamics of the protein utilizing MD simulation and that too on a long-time scale of 100 ns, with such structures being subjected to docking of small molecules. We have additionally performed MM-GBSA for the top three drug molecules along with Remdesivir as a control. This has further increased the reliability of our *insilico* analysis, unlike others. Our MD simulation studies revealed that Penciclovir formed four new H-bonds with ASP623, ARG553, ARG555 and THR556 as compared to the pre-simulation docking results. This is a new finding previously not reported by Zhang et al. (49) (Fig. 7) and indicates potential specificity of Penciclovir for nsp12. Current study has also evaluated all possible non-covalent bonds including H-bonds, van der Waals forces, electrostatic interactions and hydrophobic interactions between the drugs and the amino acid residues of nsp12 in the vicinity. This will help future lead optimization, if any, for not only the leads we identified but also for Remdesivir to identify potent inhibitor of RdRp.

The key implications of the study are manifold. Prior to our study only Remdesivir had been experimentally shown to bind RdRp of SARS-CoV-2 proteome, while after uploading the current work and its findings as a preprint (Dey et al, 2020), a cryo-EM structure (PDB Id: 7D4F; Yin, W et al., 2020) is solved showing RdRp bound to suramin thus validating our *insilico* findings. We expect similar findings with Anidulafungin and Penciclovir in the near future. Also, our study has not only included FDA

approved compounds but also WHO suggested compounds, thereby increasing the scope for drug-repurposing. Drug repurposing will allow direct human trials and help avoid delay in conducting PK-PD studies first, since these drugs are already approved for human consumption. This can speed up the process of therapeutic development against SARS-CoV-2. This is the only study so far which could identify three small molecules (i.e. Suramin, Anidulafungin and Penciclovir) with similar binding energies to Remdesivir indicating that they can be equally potent inhibitors of RdRp. Moreover, the recently evolved SARS-CoV-2 strains that are 58 times more infectious in the UK (VOC 202012/01, a.k.a. B.1.1.7), South Africa (501Y.V2, a.k.a. B.1.351) and Nigeria (B.1.207), have mutations mainly in the S protein (including N501Y) thus rendering the S protein less amenable as drug target. Thus, our approach with nsp12 as target holds promise against COVID-19 UK, SA and Nigeria strains as well. The three leads identified in the current study can at least be used as alternate monotherapies or combination therapies along with Remdesivir to combat COVID-19.

Acknowledgements

SKD is thankful to Professor Eddy Arnold, Rutgers University, USA, for the opportunity to carry out some of the investigation in his laboratory; the University of Delhi and its Dr. B.R. Ambedkar Center for Biomedical Research (ACBR) to conduct the updated experiments and providing infrastructures as well as financial support for the same. MS and SB acknowledge the Department of Biotechnology (DBT), Government of India for their project and research fellowships, respectively. CD appreciates the financial support from Lady Tata Memorial Trust in the form of a research fellowship. ASR is thankful to the Government of Odisha for the Biju Patnaik Research Fellowship. SK appreciates financial support over the years from DBT, University Grants Commission (UGC), Defence Research and Development Organization (DRDO) and Department of Science and Technology (DST), Government of India. SK is thankful to the University of Delhi, Institution of Eminence, for support in all forms.

Declaration of interest statement:

The authors declare no conflict of interest.

References:

1. Bogoch II, Watts A, Thomas-Bachli A, Huber C, Kraemer MUG, Khan K. Pneumonia of unknown aetiology in Wuhan, China: potential for international spread via commercial air travel. *Journal of Travel Medicine*. 2020;27(2).
2. Hui DS, Azhar EI, Madani TA, Ntoumi F, Kock R, Dar O, et al. The continuing 2019-nCoV epidemic threat of novel coronaviruses to global health - The latest 2019 novel coronavirus outbreak in Wuhan, China. *International Journal of Infectious Disease*. 2020;91:264-6.
3. Morens DM, Daszak P, Taubenberger JK. Escaping Pandora's Box - Another Novel Coronavirus. *New England Journal of Medicine*. 2020;382:1293-5.
4. Kirchdoerfer RN, Ward AB. Structure of the SARS-CoV nsp12 polymerase bound to nsp7 and nsp8 co-factors. *Nature Communications*. 2019;10(1):2342.
5. Courouble VV, Dey SK, Yadav R, Timm J, Harrison JJE, Ruiz FX, et al. Revealing the Structural Plasticity of SARS-CoV-2 nsp7 and nsp8 Using Structural Proteomics. *Journal of the American Society for Mass Spectrometry*.
6. Te Velthuis AJ, Arnold JJ, Cameron CE, van den Worm SH, Snijder EJ. The RNA polymerase activity of SARS-coronavirus nsp12 is primer dependent. *Nucleic Acids Research*. 2009;38(1):203-14.
7. Mirza MU, Froeyen M. Structural Elucidation of SARS-CoV-2 Vital Proteins: Computational Methods Reveal Potential Drug Candidates Against Main Protease, Nsp12 RNA-dependent RNA Polymerase and Nsp13 Helicase. *Preprints*. 2020.

8. Rizwan T, Kothidar A, Meghwani H, Sharma V, Shobhawat R, Saini R, et al. Comparative analysis of SARS-CoV-2 envelope viroporin mutations from COVID-19 deceased and surviving patients revealed implications on its ion-channel activities and correlation with patient mortality. *Journal of Biomolecular Structure and Dynamics*. 2021;1-16.
9. Elfiky AA, Elshemey WM, Gawad WA. 2'-Methylguanosine Prodrug (IDX-184), Phosphoramidate Prodrug (Sofosbuvir), Diisobutyl Prodrug (R7128) Are Better Than Their Parent Nucleotides and Ribavirin in Hepatitis C Virus Inhibition: A Molecular Modeling Study. *Journal of Computational and Theoretical Nanoscience*. 2014;12:376–86.
10. Elfiky AA, Elshemey WM. Molecular dynamics simulation revealed binding of nucleotide inhibitors to ZIKV polymerase over 444 nanoseconds. *Journal of Medical Virology*. 2018;90(1):13-8.
11. Elfiky AA, Ismail AM. Molecular modeling and docking revealed superiority of IDX-184 as HCV polymerase inhibitor. *Future Virology*. 2017;12(7):339–47.
12. Elfiky AA, Ismail AM. Molecular docking revealed the binding of nucleotide/side inhibitors to Zika viral polymerase solved structures. *SAR QSAR Environmental Research*. 2018;29(5):409-18.
13. Elfiky AA, Mahdy SM, Elshemey WM. Quantitative structure-activity relationship and molecular docking revealed a potency of anti-hepatitis C virus drugs against human corona viruses. *Journal of Medical Virology*. 2017;89(6):1040-7.
14. Ganesan A, Barakat K. Solubility: A speed-breaker on the drug discovery highway. *MOJ Bioequivalence & Bioavailability* 2017;3(3):56-8.
15. Canrong W, Yang L, Yueying Y, Peng P, Wu Z, Yali W, et al. Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods. *Acta Pharmaceutica Sinica B*. 2020.
16. Narayanan N, Nair DT. Vitamin B12 May Inhibit RNA-Dependent-RNA Polymerase Activity of nsp12 from the SARS-CoV-2 Virus. Preprints. 2020.
17. Ahmad M, Dwivedy A, Mariadasse R, Tiwari S, Jeyakanthan J, Biswal BK. Prediction of small molecule inhibitors targeting the novel 1coronavirus (SARS-CoV-2) RNA-dependent RNA polymerase2. *OSF Preprints*. 2020.
18. Patra A, Bhavesh NS. Virtual screening and molecular dynamics simulation suggest Valproic acid Co-A could bind to SARS-CoV2 RNA depended RNA polymerase. Preprints. 2020.
19. Deng CX. The global battle against SARS-CoV-2 and COVID-19. *International Journal of Biological Sciences* 2020;16(10):1676–7.
20. Ju J, Li X, Kumar S, Jockusch S, Chien M, Tao C, et al. Nucleotide Analogues as Inhibitors of SARS-CoV Polymerase *bioRxiv* 2020.
21. Elfiky AA. Ribavirin, Remdesivir, Sofosbuvir, Galidesivir, and Tenofovir against SARS-CoV-2 RNA dependent RNA polymerase (RdRp): A molecular docking study. *Life Sciences*. 2020.
22. Gao Y, Yan L, Huang Y, Liu F, Zhao Y, Cao L. Structure of RNA-dependent RNA polymerase from 2019-nCoV, a major antiviral drug target. *bioRxiv*. 2020.
23. Corpet F. Multiple sequence alignment with hierarchical clustering. *Nucleic Acids Research*. 1988;16(22):10881-90.
24. Robert X, Gouet P. Deciphering key features in protein structures with the new ENDscript server. *Nucleic Acids Research*. 2014;42(W1):W320-W4.
25. Waterhouse A, Bertoni M, Bienert S, Studer G, Tauriello G, Gumienny R, et al. SWISS-MODEL: homology modelling of protein structures and complexes. *Nucleic Acids Research*. 2018;46(W1):W296-W303.
26. Pettersen EF, Goddard TD, Huang CC, Couch GS, Greenblatt DM, Meng EC. UCSF Chimera—a visualization system for exploratory research and analysis. *Journal of Computational Chemistry*. 2004;25(13):1605-12.
27. Grosdidier A, Zoete V, Michielin O. SwissDock, a protein-small molecule docking web service based on EADock DSS. *Nucleic Acids Research*. 2011;39(Web Server issue):W270–W7.
28. Schrodinger L. Schrodinger software suite. New York: Schrödinger, LLC. 2011;670.
29. Azam F, Taban IM, Eid EE, Iqbal M, Alam O, Khan S, et al. An in-silico analysis of ivermectin interaction with potential SARS-CoV-2 targets and host nuclear importin α . *Journal of Biomolecular Structure and Dynamics*. 2020:1-14.
30. Celik S, Albayrak AT, Akyuz S, Ozel AE. Synthesis, molecular docking and ADMET study of ionic liquid as anticancer inhibitors of DNA and COX-2, TOPII enzymes. *Journal of Biomolecular Structure and Dynamics*. 2019.
31. Wang Z, Wang X, Li Y, Lei T, Wang E, Li D, et al. farPPI: a webserver for accurate prediction of protein-ligand binding structures for small-molecule PPI inhibitors by MM/PB (GB) SA methods. *Bioinformatics*. 2019;35(10):1777-9.
32. Hinsen K. The molecular modeling toolkit: a new approach to molecular simulations. *Journal of Computational Chemistry*. 2000;21(2):79-85.
33. Robertson MJ, Tirado-Rives J, Jorgensen WL. Improved peptide and protein torsional energetics with the OPLS-AA force field. *Journal of Chemical Theory and Computation*. 2015;11(7):3499-509.
34. Shivakumar D, Harder E, Damm W, Friesner RA, Sherman W. Improving the prediction of absolute solvation free energies using the next generation OPLS force field. *Journal of Chemical Theory and Computation*. 2012;8(8):2553-8.
35. Guvench O, MacKerell AD. Comparison of protein force fields for molecular dynamics simulations. *Molecular Modeling of Proteins*. 2008;443:63-88.
36. Wang J, Wang W, Kollman PA, Case DA. Automatic atom type and bond type perception in molecular mechanical calculations. *Journal of Molecular Graphics and Modelling*. 2006;25(2):247-60.
37. Darden T, York D, Pedersen L. Particle mesh Ewald: An $N \cdot \log(N)$ method for Ewald sums in large systems. *The Journal of Chemical Physics*. 1993;98(12):10089-92.

38. Boulanger E, Huang L, MacKerell AD, Roux B. Improved Lennard-Jones Parameters for Accurate Molecular Dynamics Simulations. *Biophysical Journal*. 2016;110(3):646a.
39. Mackowiak S, Pieprzyk S, Branka A, Heyes D. A Nosé-Hoover Thermostat Adapted to a Slab Geometry. *Computational Methods in Science and Technology*. 2017;23(3):211-8.
40. Bereau T. Multi-timestep integrator for the modified Andersen barostat. *Physics Procedia*. 2015;68:7-15.
41. Kumari R, Kumar R. C. Open source drug discovery and A. Lynn. *J Chem Inf Model*. 2014;54(1951):10.1021.
42. Kuhn B, Kollman PA. Binding of a diverse set of ligands to avidin and streptavidin: an accurate quantitative prediction of their relative affinities by a combination of molecular mechanics and continuum solvent models. *Journal of medicinal chemistry*. 2000;43(20):3786-91.
43. Vanommeslaeghe K, Hatcher E, Acharya C, Kundu S, Zhong S, Shim J, et al. CHARMM general force field: A force field for drug-like molecules compatible with the CHARMM all-atom additive biological force fields. *Journal of computational chemistry*. 2010;31(4):671-90.
44. Wang E, Sun H, Wang J, Wang Z, Liu H, Zhang JZ, et al. End-point binding free energy calculation with MM/PBSA and MM/GBSA: strategies and applications in drug design. *Chemical reviews*. 2019;119(16):9478-508.
45. Li J, Abel R, Zhu K, Cao Y, Zhao S, Friesner RA. The VSGB 2.0 model: a next generation energy model for high resolution protein structure modeling. *Proteins: Structure, Function, and Bioinformatics*. 2011;79(10):2794-812.
46. Harder E, Damm W, Maple J, Wu C, Reboul M, Xiang JY, et al. OPLS3: a force field providing broad coverage of drug-like small molecules and proteins. *Journal of chemical theory and computation*. 2016;12(1):281-96.
47. Lu R, Zhao X, Li J, Niu P, Yang B, Wu H, et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. *The Lancet*. 2020;395(10224):565-74.
48. Fani M, Teimoori A, Ghafari S. Comparison of the COVID-2019 (SARS-CoV-2) pathogenesis with SARS-CoV and MERS-CoV infections. *Future Virology*. 2020(0).
49. Zhang W, Stephen P, Thériault J-F, Wang R, Lin S-X. Novel Coronavirus Polymerase and Nucleotidyl-Transferase Structures: Potential to Target New Outbreaks. *The Journal of Physical Chemistry Letters*. 2020.
50. Simonis A, Theobald SJ, Fätkenheuer G, Rybníček J, Malin JJ. A comparative analysis of remdesivir and other repurposed antivirals against SARS-CoV-2. *EMBO Molecular Medicine*. 2020:e202013105.
51. Kaddoura M, Allbrahim M, Hijazi G, Soudani N, Audi A, Alkalamouni H, et al. COVID-19 therapeutic options under investigation. *Frontiers in Pharmacology*. 2020;11.
52. Dey SK, Saini M, Dhembla C, Bhatt S, Rajesh AS, Anand V, et al. Suramin, Penciclovir and Anidulafungin bind nsp12, which governs the RNA-dependent-RNA polymerase activity of SARS-CoV-2, with higher interaction energy than Remdesivir, indicating potential in the treatment of COVID-19 infection. *OSF Preprints*. 2020 DOI: 10.31219/osf.io/urxwh.
53. Ruan Z, Liu C, Guo Y, He Z, Huang X, Jia X, et al. Potential inhibitors targeting RNA-dependent RNA polymerase activity (NSP12) of SARS-CoV-2. *Preprints*. 2020.
54. Warren TK, Jordan R, Lo MK, Ray AS, Mackman RL. Therapeutic efficacy of the small molecule gs-5734 against Ebola virus in rhesus monkeys. *Nature*. 2016;531:381-5.
55. Selisko B, Papageorgiou N, Ferron F, Canard B. Structural and Functional Basis of the Fidelity of Nucleotide Selection by Flavivirus RNA-Dependent RNA Polymerases. *Viruses*. 2018;10(2):59.
56. National Center for Biotechnology Information. PubChem Database. Penciclovir, CID=135398748.
57. Bacon TH, Levin MJ, Leary JJ, Sarisky RT, Sutton D. Herpes simplex virus resistance to acyclovir and penciclovir after two decades of antiviral therapy. *Clinical and Microbiological Review*. 2003;16(1):114-28.
58. Kathryn S, Gumbo T. Anidulafungin in the treatment of invasive fungal infections. *Therapeutics and Clinical Risk Management*. 2008;4(1):71-8.
59. Stein CA. Suramin: A Novel Antineoplastic Agent with Multiple Potential Mechanisms of Action. *Cancer Research*. 1993;53(10):2239-48.
60. Li H, Li H, Qu H, Zhao M, Yuan B, Cao M, et al. Suramin inhibits cell proliferation in ovarian and cervical cancer by downregulating heparanase expression. *Cancer Cell International*. 2015;15(1):52.
61. Cheson BD, Levine AM, Mildvan D. Suramin Therapy in AIDS and Related Disorders: Report of the US Suramin Working Group. *Journal of the American Medical Association*. 1987;258(10):1347-51.
62. Croci R, Pezzullo M, Tarantino D, Milani M, Tsay S-C, Sureshbabu R, et al. Structural bases of norovirus RNA dependent RNA polymerase inhibition by novel suramin-related compounds. *PLoS One*. 2014;9(3):e91765.
63. da Silva CSB, Thaler M, Tas A, Ogando NS, Bredenbeek PJ, Ninaber DK, et al. Suramin inhibits SARS-CoV-2 infection in cell culture by interfering with early steps of the replication cycle. *Antimicrobial Agents and Chemotherapy*. 2020.
64. Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. *Cell Research*. 2020;30(3):269-71.
65. Jeon S, Ko M, Lee J, Choi I, Byun SY, Park S, et al. Identification of antiviral drug candidates against SARS-CoV-2 from FDA-approved drugs. *Antimicrobial Agents and Chemotherapy*. 2020.
66. Sharma J, Bhardwaj VK, Singh R, Rajendran V, Purohit R, Kumar S. An in-silico evaluation of different bioactive molecules of tea for their inhibition potency against non structural protein-15 of SARS-CoV-2. *Food chemistry*. 2021;346:128933.

67. Bhardwaj VK, Singh R, Das P, Purohit R. Evaluation of acridinedione analogs as potential SARS-CoV-2 main protease inhibitors and their comparison with repurposed anti-viral drugs. *Computers in biology and medicine*. 2021;128:104117.
68. Bhardwaj VK, Singh R, Sharma J, Rajendran V, Purohit R, Kumar S. Identification of bioactive molecules from tea plant as SARS-CoV-2 main protease inhibitors. *Journal of Biomolecular Structure and Dynamics*. 2020:1-10.
69. Ghosh R, Chakraborty A, Biswas A, Chowdhuri S. Computer aided identification of potential SARS CoV-2 main protease inhibitors from diterpenoids and biflavonoids of *Torreya nucifera* leaves. *Journal of Biomolecular Structure and Dynamics*. 2020:1-16.
70. Mutlu O, Ugurel OM, Sariyer E, Ata O, Inci TG, Ugurel E, et al. Targeting SARS-CoV-2 Nsp12/Nsp8 interaction interface with approved and investigational drugs: an in silico structure-based approach. *Journal of Biomolecular Structure and Dynamics*. 2020:1-13.